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ABSTRACT 
 
Mucosal associated invariant T (MAIT) cells are a fairly recently described population 
of innate-like T cells. In humans, MAIT cells represent an exceptionally abundant 
population in the blood, where they account for 1–10% of all T cells. However, 
compared to conventional T cells, which can display an almost unlimited T cell receptor 
(TCR) repertoire, the specificities of MAIT cell TCRs are limited. This evolutionarily 
conserved subset displays a semi-invariant TCR which recognises riboflavin 
metabolites, produced by a wide range of bacteria and fungi, and presented on the 
major histocompatibility complex (MHC)-class I related (MR1) molecule. The function 
and significance of MAIT cells in health and disease have only started to be unravelled, 
and it is becoming increasingly clear that MAIT cells are also modulated in non-
microbial diseases. Interestingly, MAIT cells have been shown to exhibit a relatively 
high expression of the transcription factor, Helios, compared to most other T cell 
subsets. The function of this translational activator and repressor, encoded by the gene 
IKZF2, in the MAIT cell population remains obscure. This study focused on the 
functional role Helios may play in regulating the activation of MAIT cells. Thus, by using 
siRNA to silence Helios expression, and flow cytometry to analyse any potential 
alterations in MAIT cell activation markers, we aimed to be able to characterise the 
kinetics and functional role of Helios in peripheral MAIT cells of healthy individuals. 
Here, we clearly established a striking upregulation of Helios in MAIT cells following 24 
hours of stimulation. Moreover, we were able to achieve a >50% knockdown of Helios 
at the protein level, in this subset of T cells. Nevertheless, no significant difference in 
any of the activation markers we investigated was present between the MAIT cells with 
reduced Helios expression and their controls. This could, however, of occurred as a 
result of the toxicity that the transfection had on the functionally of the T cells. From 
these results, it is difficult to conclude any clear role for Helios in the activation of MAIT 
cells, and consequently, further research needs to be performed before any clear 
conclusions can be drawn. 
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LIST OF ABBRIVIATIONS 
ALL    Acute lymphoblastic leukaemia  
AML    Acute myeloid leukaemia 
APC     Antigen-presenting cell 
BSA    Bovine serum albumin  
CCR    CC chemokine receptor 
CD    Cluster of differentiation 
CD4+    CD8- CD4+ cell 
CD8+     CD8+ CD4- cell 
CXCR    CX chemokine receptor 
DAMPs   Damage associated molecular patterns 
DC    Dendritic cell 
DCM    Dead cell marker 
DN    Double negative, CD8- CD4- cell 
DP    Double positive, CD8+ CD4+ cell 
E. coli    Escherichia coli 
EDTA    Ethylenediaminetetraacetic acid 
FACS    Fluorescent-activated cell sorting  
FBS    Foetal bovine serum 
Grz    Granzyme 
HCV    Hepatitis C virus  
HIV    Human immunodeficiency viruses 
INF    Interferon 
IKZF2    IKAROS family zinc finger 2 (also known as Helios) 
IL    Interleukin  
JAK    Janus kinase 
KD    Knockdown 
μ    Micro (106) 
mAbs    Monoclonal antibodies 
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MACS    Magnetic-activated cell sorting 
MAIT cell   Mucosal associated invariant T cell 
MFI     Median fluorescence intensity  
MHC    Major histocompatibility complex 
MR1    Major histocompatibility complex class-I related 
NK cell   Natural killer cell 
NKT    Natural killer T cell 
NURD    Nucleosome remodelling and deacetylase 
PAMP    Pathogen-associated molecular pattern 
PBMC    Peripheral blood mononuclear cell 
PBS    Phosphate-buffered saline 
PLZF    Promyelocytic leukaemia zinc finger 
pmol    Picomole 
PMTs    Photomultiplier tubes 
Prf    Perforin  
RORyt    Retinoid-related orphan receptor yt 
rpm    Revolutions per minute 
RT    Room temperature 
siRNA    Small interfering ribonucleic acid 
STAT    Signal Transducer Activator of Transcription 
Tbet    T-box binding transcription factor 
TCR    T cell receptor 
Th    T helper 
TLR    Toll-like receptor 
TNF    Tumour necrosis factor 
Treg    T regulatory  
5-OE-RU   5-(2-oxoethylideneamino)-6-D-ribitylaminouracil 
5-OP-RU   5-(-2-oxopropylideneamino)-6-D-ribitylaminouracil 
6-FP    6-formylpterin   
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1  INTRODUCTION 
 
In a world so abundantly populated with pathogens, the human body has developed 
multidimensional protective mechanisms that together constitute the immune 
system. This amazingly complex system can recognise, and hence protect from, 
millions of pathogenic microbes that individuals may have never before encountered. 
 
However, like any system, the immune system has the ability to malfunction, which 
leads to the development of autoimmune diseases allergy and even 
immunodeficiencies. T cells play a significant role in the maintenance of tolerance in 
health, but also when immune dysregulation occurs, they have a direct role in the 
development of tissue damage, which encompasses autoimmune diseases. 
Consequently, T cells should be viewed as a profoundly important target for 
pathologies associated with the disturbances of the immune system. Thus, gaining a 
more comprehensive understanding of T cell immunology will contribute to the 
development of new therapies that can treat the cause of these diseases. Moreover, 
the potent effector phenotype that T cells display have the potential to be utilised 
and specifically augmented against targets for treatments of other conditions such as 
cancers. 
 
Ultimately, a deeper understanding of T cell differentiation, diversity, dynamics, 
repertoires selection, and regulation processes is critical for the advancement of 
fundamental research, and thus, for the innovation of new medical treatments and 
drug discovery. 
 
Here, we aim to provide further knowledge on the function and regulation of a subset 
of T cells known as mucosal-associated invariant T cells, by exploring the role of the 
transcription factor Helios in the activation of these T cells. 
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2  LITERATURE REVIEW 
 
2.1 The Immune System 
 
The immune system is a continually evolving network designed to protect us from a 
world heavily populated with pathogenic microbes. It is characterised not only by its 
vast network of inter- and intra-cellular signalling but also by its exceptional 
lymphocyte receptor diversity, its capacity to migrate throughout the body, maintain 
homeostatic regulation, and rapidly adapt to a changing environment1,2,3. To simplify 
this complexity, the immune system is often described as having two fundamental 
lines of defence: the innate and adaptive immune response, in which both 
mechanisms are utilised harmoniously to discriminate and eliminate dangers1,3. 
 
2.1.1 Innate Immunity  
 
Innate immunity represents the first line of defence to an intruding pathogen. It 
comprises of anatomical, physical and inflammatory barriers4. One critical defence 
mechanism that is utilised by this system is the ability to recognise pathogen-
associated molecular patterns (PAMPs), which are highly conserved structural motifs 
common to many pathogenic microbes and toxins5,6. This type of hard-wired 
response is encoded in the germline of the host, and upon activation, it incites the 
recruitment of more immune cells to sites of infection through the production of 
cytokines and chemokines3,7. Furthermore, innate immune cells are also able to 
perceive immunological ‘danger’ in the form of damage-associated molecular 
patterns, which characterise the common metabolic effects of infection and 
inflammation5,7. These are molecules that are upregulated and released during the 
cell lysis and tissue damage processes in the context of both infectious and sterile 
inflammation3,5. Additionally, innate immune receptors also detect the lack of specific 
molecules, typically expressed by normal, healthy cells but are not present on cells 
infected by microbial pathogens3,5,8. This occurs by way of the absence of an inhibitory 
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signal that would normally be delivered to prevent activation of the immune response 
against host tissues3,9. The broad ranging exploitation of these recognition molecules 
across a large number of cells within the innate immune system, such as dendritic 
cells, macrophages, neutrophils, mast cells, basophils, eosinophils, natural killer (NK) 
cells and innate lymphoid cells, is the basis for why the system is poised to act 
rapidly10. Speed is a defining feature of the innate immunity. Within minutes of 
exposure to a pathogen the innate immune system generates a protective 
inflammatory response, and hence constitutes the initial host response3,11. Soluble 
proteins also facilitate this rapid response for instance; complement proteins that are 
constitutively present in biological fluids, and small bioactive molecules like cytokines 
that regulate the function of other cells, or chemokines that attract inflammatory 
leukocytes, and lipid mediators of inflammation1,3. While innate immunity is essential 
for defence against pathogenic challenges, it is also emerging as a key regulator of 
human inflammatory disease12,13. Additionally, innate immunity plays a central role in 
initiating the subsequent adaptive immune response, and in order to avoid damage 
to self-tissues, it is essential that the entirety of immune response is able to avoid the 
destructive mechanisms against the mammalian host’s own tissues. 
 
2.1.2 Adaptive Immunity  
 
The adaptive immune system has evolved into a system of billions of highly diversified 
lymphocytes all interacting as a connective dynamic multi-scale network, to ensure a 
sophisticated immune response. The response of the adaptive immune system is 
triggered when the innate immune response is insufficient to control an infection14. 
Synergy between these two arms is fundamental for an intact, fully effective immune 
response3. The overwhelming variability of antigenic structures, as well as the ability 
of pathogens to mutate to avoid host detection has driven the evolution of the 
adaptive immune system. The adaptive response primarily involves the expression of 
antigen-specific receptors on the surfaces of T- and B- lymphocytes and a tightly 
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regulated interplay between antigen presenting cells (APCs)15. During lymphocyte 
development, these antigen-specific receptors are selected and precisely tailored by 
a process of somatic recombination, ensuring that their diverse repertoire bind 
appropriately to the corresponding antigen and are not self-reactive16,17,18. Upon 
recognition of their corresponding antigen, lymphocytes undergo clonal expansion, 
which facilitates pathogen-specific immunological effector functions17. Effector 
pathways of the adaptive system are classically described as either humoral or cell 
mediated. The humoral immune system is typically associated with the functions of B 
lymphocytes, and targets antigens from pathogens that are freely circulating, or 
displayed on the exterior of infected cells19. Cellular immunity, however, directs it 
effector mechanisms towards intracellularly infected cells and is mediated by T 
lymphocytes20. Following a response to a particular pathogen, the adaptive immune 
system also evolves a memory to provide the host with long-term protection from 
reinfection from the same pathogen and on re-exposure; this memory facilitates faster 
and more effective response21,22.  
 
2.1.3 T Cells and Their Function in the Immune System  
 
T lymphocytes are a fundamental part of the adaptive immune system. Their roles 
encompass the direct elimination of infected host cells, activation of other immune 
cell populations, the production of cytokines and regulation of the immune 
response23. These key features of T cell responsiveness are established during their 
development in the thymus, upon the production of their characteristic surface 
receptors, known as T cell receptors (TCRs) which essentially programme their 
capacity to protect the body against a diverse range of pathogens, while maintaining 
tolerance to self-antigens16,17,18,24. TCRs are expressed at the cell surface as a complex, 
which contains signalling chains TCRζ and CD3 complex that generate intracellular 
signals upon antigen recognition. The heterodimeric TCRs consist of two distinct 
polypeptide chains, linked by a disulphide bond. Each T cell expresses monospecific 
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TCR complexes where all receptor complexes in a given cell harbours the same 
uniquely rearranged TCRα and TCRβ sequence, which is typically specific to a single 
antigen25. The diversity that is required to generate unique TCR complexes for each 
T cell is vast and commands a complex mechanism involving the rearrangement of 
the germline TCR  genes17,18,26. Each TCR locus contains numerous copies of DNA 
segments which encode the variable domain of each TCR chain, and are denoted as 
variable (V), Joining (J) and, for the TCRβ and TCRδ chain, Diversity (D). Such copies 
differ in their sequence and are arranged to include a single copy of each V, D and J 
segment17. Moreover, further diversification results from nucleotide deletions and 
non-templated additions that are produced during the joining process18. The 
structural formation of the α and β chains resulting from the rearrangement have 
three hypervariable complementarity determining regions, the third of which has the 
most polymorphism and hence has the primary role in distinguishing the peptide26. 
The diversity of TCR repertoire that this process produces primes T cells for the 
recognition of a whole spectrum of antigens, however the ability of T cells to 
recognise these antigens typically requires their presentation by other immune 
populations known as, antigen-presenting cells (APCs), hence partially restricting the 
capacity of T cells to activate their effector functions27,28. 
 
2.1.4 Antigen Presentation and T Cell Activation 
 
In the presence of infection or inflammation, APCs such as dendritic, macrophage   
and also B cells, present antigens on the “classical” major histocompatibility complex 
molecules, class I (MHC-I) or class II (MHC-II), that have the potential to activate T 
cells17,29. Antigen recognition occurs through the interaction between the two TCR 
chains with both the corresponding peptide antigen and MHC amino acid residues. 
Upon identification of a specific MHC-peptide complex, such T cells proliferate and 
acquire properties of a mature T cell, such as cytokine production or expression of 
specific surface molecules18. Whether T cells recognise MHC I or MHC II depends on 
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their co-receptor expression, which is determined during T cell development in the 
thymus30. These two surface glycoproteins contribute to the recognition of MHC 
molecules and signalling by T cells. CD8+ T cells identify antigen peptides bound to 
the MHC I molecules and CD4+ T cells peptides bound to MHC II molecules31,32. Both 
CD4+ and CD8+ subsets have distinct functional roles within the immune system. 
Naive CD4+T cells are activated after interaction with antigen-MHC II complex on 
APCs and differentiate into discrete effector subtypes, depending largely on the 
cytokine milieu of the microenvironment33. Collectively, CD4+ T cells are often 
referred to as helper T cells (Th) as they are chiefly responsible for the activation of 
other cells within the immune system such as B-lymphocytes and CD8+ T cells. 
However, some subtypes also play a vital role in the suppression of immune reaction 
(regulatory T cells, Tregs) 18. CD8+, on the other hand, recognises MHC I, which are 
expressed by all the nucleated cells and primarily presents peptides derived from 
intracellular degradation of proteins. The pathogen-derived antigen presented in the 
MHC I molecule indicates an intracellular infection and directs cytotoxic CD8+ T cells 
to kill the infected cell34.  
 
The immune system is exceptionally potent, particularly the T cell response. Evidently 
this response has the clear potential to exhibit destructive effects on one’s own tissues 
when mediation is impaired35.  Therefore, it requires tight regulation. Three signals 
are required for conventional T cell activation: TCR-MHC: peptide-interaction, a co-
stimulatory signal that is provided by CD28 and CD80/CD86, and cytokines36. 
Crucially, the third signal, derived from the cytokine environment, drives CD4+ T 
helper cell subset differentiation37. 
 
2.1.5 Th Responses 
 
T lymphocytes depend upon the function of immunological networks that initiates, 
guides and controls them. The specific binding of cytokines with their receptors on 
helper T cells results in the stimulation of JAK/STAT pathways, and ultimately leads 
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to the augmented expression of subset-specific genes, including those that encode 
“lineage-defining” transcription factors38,39. Immune reactions in vivo constitute 
several different Th response types, and it is the balance between these that 
determine the immunological outcomes. The influential research conducted by 
Mosmann and Coffman in 1986 found that naïve CD4+ T cells were able to 
differentiate into two distinct subsets, either T helper 1 (Th1) or Th240. This discovery 
launched a new field of immunological investigation designed to understand the 
mechanisms that underlie the functional diversity of CD4+ subsets. For a long period, 
many thought that only the original Th1 and Th2 subsets existed. However, more 
recent research has shown that T helper cells are not only limited to these two subsets 
but have been expanded to include the subpopulations now classified as Th17, 
follicular helper T cells (Tfh), and induced Tregs41,42,43. As evident by these described 
populations, CD4+ T helper cells are capable of differentiating into a number of 
effector subsets that each provide discrete functions during an adaptive immune 
response (Figure 1). Environmental cytokine signals largely govern the 
differentiation of each of these subsets and the subsequent activation of downstream 
transcription factor pathways. However, plasticity between these response types have 
also been observed44. The diverse functions executed by these subpopulations 
permit an extremely tailored pathogen-specific immune response to bacterial, viral, 
and parasitic infections. 
 
The Th1 cells are critical in the response against intracellular bacteria, fungi and 
protozoa40. The secretion of IFN-γ, and lymphotoxin-α are characteristic of this 
subset, and results in the enhanced antimicrobial activity of macrophages and DCs, 
thus, augmenting their ability to eradicate intracellular microbes and their ability to 
present antigens45. Moreover, this response is aided through the direct interaction of 
CD40-L with CD40R on the surface of APCs46. Naïve CD4+ T cells are induced into 
the Th1 lineage by early exposure to several cytokines, but the two most critical at 
the time of T cell priming are IFN-γ and IL-12, with the initial sources of these signals 
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thought to derive from NK cells and DCs, respectively45. Through the activation of the 
STAT 1 pathway, IFN-γ induces the expression of T-bet, a Tbox transcriptional 
regulator, that in turn promotes the upregulation of IFN-γ in a positive feedback loop, 
but also results in the suppression of IL-4 expression, a cytokine known to promote 
Th2 differentiation47. IL-12, however, operates through a distinct STAT4-dependent 
pathway to enhance production of IFN-γ, and additionally, it triggers the 
upregulation of its own receptor and that of IL-1848. Moreover, Th1 cells have been 
known to produce IL-2, a proinflammatory cytokine that induces T cell proliferation, 
and TNFα, a cytokine responsible for the activation of epithelium at the site of 
infection49. Collectively, these effects result in the amplification of the Th1 response. 
 
 
 
 
 
 
 
 
 
The Th2 cellular response is synonymous with targeting parasitic infection40. A range 
of Th2-associated cytokines, including IL-4, IL-5, IL-10, and IL-13, mediate the 
orchestration of the response40,50. In this setting, Th2 cells stimulate humoral immunity 
through the production of IL-4 by regulating the induction of B cell IgE antibody 
isotype switching51. IgE immune complexes are responsible for cross-linking high-
affinity Fc receptors for IgE (FcεRI) on the surface of innate immune cells such as 
eosinophil, mast cells and basophils, resulting in their activation. Additionally, IL-5 
stimulates the proliferation and differentiation of eosinophils, while IL-13 enhances B 
cell proliferation and isotype switching and inhibits the production of anti-
inflammatory cytokines52. Once activated, basophils and mast cells secrete various 
Figure 1. Differentiation of naïve CD4 T cells into Th1, Th2 and Th17 Effector Cells. 
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products, including histamine, serotonin and proteases, as well as several cytokines 
and chemokines, which result in smooth muscle constriction, vascular permeability 
and the recruitment of more pro-inflammatory cells53. Furthermore, the expression of 
FcεRI is further upregulated on these cells as a result of the IgE cross-linking, hence, 
provides a potent amplification of IgE-mediated Th2-type effector responses54. The 
generation of the Th2 response occurs when naïve CD4+ T cells are exposed to IL-4 
at the time of T cell priming. In low antigen conditions, responding T cells produce 
IL-4, however, in an activated state, innate cells such as eosinophils, mast cells and 
basophils also contribute to its production50. Recent work demonstrates that through 
interaction with its receptor, IL-4 activates STAT655. The fundamental role of STAT6 
in Th2 differentiation is further supported by a profound decline in the development 
of this lineage observed in Stat6-deficient mice56. It is now known that the activation 
of STAT6 leads to its nuclear translocation and subsequent induction of the 
transcription factor GATA3, which, like T-bet for Th1 cells, is considered the master 
regulator of Th2 differentiation. Thus, the mature Th2 cell’s production of IL-4 acts in 
a positive feedback loop to promote further Th2 cell differentiation in naive T cells as 
they encounter antigen. Nevertheless, a Th2 response has the potential to contribute 
to pathologic conditions of allergy and airway hypersensitivity, when inappropriately 
regulated57,58. 
 
The Th17 type response was first described in 2005 as having a primary function to 
protect against extracellular bacteria and fungi41. Since then, many studies have 
further investigated their immune function and the mechanisms that regulate this 
function59,60,61. It is now understood that in the presence of IL-6 and TGF-b, but 
absence of IL-4 and IL-12, naïve CD4+ are induced to Th17 lineage, and that their 
defining characteristic is the expression of the transcription factor RORγt, as well as 
the expression of IL-17A and IL-17F, as their classification name suggests60. The 
differentiation of Th17 cells is controlled by the transcription factor RORγt, which is 
considered the “master-regulator” as it directs the specific and heritable gene 
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expression profile of the subset59. Th17 cells are not only considered to be distinct 
from the other Th cells by their gene expression and regulation, but also in terms of 
their biological function. Th17 cells, by virtue of their production of IL-17, are 
generally thought to be pro-inflammatory and play an important role in host defence 
against infection, by recruiting neutrophils and macrophages to infected tissues, and 
although the hallmark of Th17 cells is the expression of IL-17, additional cytokines 
have been identified such as IL-21 and IL-2260. The expression of IL-21 is dependent 
on STAT3-mediated IL-6 signalling in Th17 cells and is thought to act in synergy with 
TGFβ to promote Th17 differentiation61. Moreover, the IL-21 receptor, composed of 
IL-21R and the common γ chain, has been shown to be expressed by Th17 cells, and 
thus can act in an autocrine manner60. Th17-secreted IL-22, however, induces the 
expression of anti-microbial peptides beta-defensin-2 and beta-defensin-3 upon 
binding to its receptor on target cells62. Recently, it was demonstrated that IL-22 is 
able to protect hosts against bacterial infections of the lungs and gut63. The Th17 
response has however been suggested to be complicit in autoimmune diseases64,65. 
 
While a considerable proportion of research has focused on T cells that recognise 
peptides presented in major histocompatibility complex (MHC) proteins, numerous 
other subtypes do not fit this paradigm. Somewhere between the rapid sensing and 
wide ranging innate immune system and the finely tuned repertoire of the adaptive 
system there exists a group of T cells that display both innate and adaptive 
characteristics. Collectively, they are considered “innate-like” or “unconventional” T 
cells, to a certain extent because they recognise lipids, small-molecule metabolites 
and particularly modified peptides.  
 
Restricted repertoires appear to define these discrete lymphocyte subpopulations 
that exist at the frontier between the innate and adaptive immune system. This is 
likely due to the fact limited repertoires allow for the presence of a high number of 
pre-existing cells that are responsive to phylogenetically conserved antigens66. 
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Alternatively, populations with a highly restricted repertoire could play an 
immunoregulatory or alternative physiological role67. Numerous types of so called 
“unconventional” T cells in humans have been described, including CD1 restricted T 
cells, which encompass the NKT cell population, mucosal associated invariant T cells, 
and γδ T cells named by their unique expression a gamma and delta chain TCR68,69,70. 
 
2.2 Mucosal Associated Invariant T Cells 
Mucosal associated invariant T cells (MAIT cells) are a relatively recently described 
population of innate-like T cells69. They represent a remarkably abundant population 
in human blood and liver where they account for 1–10% and 20–45% of all T cells, 
respectively. After birth, human MAIT cells expand and acquire a homogeneous 
phenotype, however, in contrast to conventional T cells, which can display an 
orthodox TCR with an almost unlimited repertoire, MAIT cells express a semi-invariant 
TCR rearrangement with limited specificities71. Despite their relative abundance and 
unique specificity, the function of MAIT cells within the immune system has yet to be 
clearly defined. Nevertheless, the field is rapidly advancing, with numerous studies 
now suggesting the significance of these cells in disease and their potential as 
therapeutic targets72,73,74,75. 
 
2.2.1 MAIT cell Identification and Phenotype 
Porcelli et al. first identified the existence of the invariant TCRα chain, Vα7.2-Jα33, 
while investigating TCRα chains of double negative T cells from peripheral blood of 
healthy individuals76. They observed the preferential pairing between the invariant 
TCR α-chain and a limited TCR β-chain repertoire. Following this discovery, Tilloy et 
al. went on to describe a homologous restricted population, with Vα19-Jα33 
rearrangement, in mice and cattle77. This discovery highlighted that this unique 
population of T cells are phylogenetically conserved, and consequently, could serve 
an historic and important physiological role in mammals. Despite the identification of 
restricted population in 1993, it was not until 2003, that Treiner et al. noticed, in a 
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landmark study, the absence of Vα19-Jα33 transcripts in MHC class I-related (MR1) 
deficient mice and thus, identified the MR1, a non-polymorphic protein, as the 
restricting molecule of this cell population78. The biological significance of this 
interaction is accentuated by the fact the genes encoding for MR1 and the invariant 
TCR are highly conserved throughout mammalian evolution, with species that lack 
MR1 also selectively lacking a TCRα chain homologous to Vα7.2-Jα33 in humans. The 
populations were termed mucosal-associated invariant T cells or MAIT cells, due to 
their relative enrichment in the gut lamina propria of humans and mice. 
 
Although Porcelli et al. first described the MAIT cell population in humans as CD4-
CD8- T cells, by the end of 1993, A. Bendelac verified the results of S. Porcelli, with a 
comprehensive study showing that the human Vα7.2-Ja33 TCRα chain was prevalent, 
not only in DN T cells, but also in the CD8+ population79. Today, the current dogma 
accepts that the majority of human MAIT cells are typically CD8+, and notably, they 
are largely CD8α+CD8β−/lo, suggesting a predominant expression of CD8αα 
homodimers, contrasting the mainly CD8αβ+ TCRs found in the conventional T cell 
populations. The other 10–20% of the MAIT cell population consists of a DN 
population, and a CD4+ subset that represents less than 5% of all MAIT cells. The 
function of CD4 and CD8 in MAIT cell biology has yet to be fully understood, as there 
is little evidence to suggest an apparent functional or phenotypic difference between 
these subsets80.  One recent study, however, has suggested that the CD4–CD8– subset 
is developmentally more mature than the main CD8+ pool81. CD4+CD8– MAIT cells on 
the other hand, are often overlooked, but are thought to signify a distinct population. 
They have been shown to produce more IL-2 than the other MAIT cell populations, 
and additionally do not show the same age-related kinetics that other MAIT cells 
demonstrate82, therefore, it is quite possible that they could have a distinct role within 
the immune system.  
Phenotypically MAIT cells express both Th1- and Th17- like features and share some 
of the same characteristics as natural killer (NK) cells, most notably, the high 
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expression of the C-type lectin CD16183. Moreover, they also display a high 
expression level of CD26, a dipeptidase processing various chemokines, growth 
factors, and neuropeptides84. The expression of homing receptors, CCR6, CXCR6, 
CCR5, CCR2, and intermediate levels of CCR9, are present at high levels, enabling 
them to migrate to the liver, gut and lung85,86. Conversely, however these cells express 
very little to no CD62L and CCR7; receptors responsible for migration into non-
inflamed lymph nodes85,87. In accordance with this, MAIT cells can be observed in the 
lungs of patients with infections such as M. tuberculosis, as well as in human gut 
samples, but are rarely detected in human lymph nodes88. MAIT cells also display the 
characteristic expression of an effector-memory phenotype CD45RAloCD45RO+ 
CD27+, yet interestingly, they are strikingly not cycling (Ki-67-) despite their high clonal 
size85,89. Furthermore, MAIT cells display a high expression of cytokine receptors such 
as IL-18Rα, IL-12R, IL-7R, and a distinctive profile of transcription factors (PLZF, 
RORγt, T-bet, Eomes and Helios)90,91,92. Finally, MAIT cells have been shown to display 
PLZF-dependent proapoptotic phenotype, as indicated by increased susceptibility to 
in vitro-induced apoptosis93. Figure 2 recapitulates the phenotype of classical 
mucosal associated invariant T cells in the peripheral blood of healthy adult 
individuals. 
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Figure 2. Phenotype of classical mucosal associated invariant T cells in the periphery 
of a healthy human adult. Expression levels are abbreviated as hi (high), int (intermediate), or 
lo (low). 
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In 2009 Martin et al. developed a monoclonal antibody (clone 3C10) that binds to the 
human TCR Vα7.2 segment94. This breakthrough enabled the identification of Vα7.2+ 
cells by flow cytometry.  Later in 2011, Le Bourhis et al. showed that the co-expression 
of the surface marker CD161 or IL-18 receptor α (IL-18Rα) with Vα7.2+ cells highly 
enriched for the MAIT cell population95. The field soon adopted the use of Vα7.2, and 
co-expression of high levels of CD161 within the T cell compartment as the primary 
method to identify MAIT cells using flow cytometry. Since then, however, the 
identification of MAIT cell agonists by Kjer-Nielsen et al. has led to the generation of 
fluorescent MR1 tetramers refolded with such compounds96. In healthy adult 
individuals, the cell population identified using MR1 tetramers greatly overlaps with 
those defined as CD161hi Vα7.2+ 82, 97. But It remains unclear how well these surrogate 
markers define these cells in other tissues or in the context of disease. 
 
2.2.2 MAIT Cell Development 
 
Like other T cells, MAIT cells develop in a thymus-dependent manner. However, in 
contrasts to conventional T cell development, in which positive selection entails the 
interaction between the TCR and MHC proteins expressed on thymic epithelial cells, 
MAIT cells are selected into the lineage by double-positive, MR1-expressing cortical 
thymocytes98,101. This occurs following the random rearrangements in TCR-encoding 
genes, where cells then generate a TCR capable of interacting with MR1. Several 
studies had initially alluded to this possibility, as they published results showing DP 
thymocytes that exhibit a high level of endogenous MR1 in both mice and 
humans99,101. Nevertheless, it was Seach et al. that went on to demonstrate the 
imperative and role of MR1-expressing DP thymocytes in MAIT cell selection, with 
the use of transgenic mouse models and thymic organ cultures101. Koay et al. went on 
to investigate MAIT cells in the thymus with the use of MR1 tetramer and proposed a 
three-stage pathway for MAIT cell development102. In humans this consists of stage 1 
containing predominantly DP and CD4+ thymocytes expressing a CD3+MR1tet+CD27–
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CD161– phenotype, stage 2  comprising of  mostly DP, CD4+ and CD8+ cells that 
display a CD3+MR1tet+CD27+CD161– expression profile and finally stage 3, which 
primarily consists of CD8+ and DN CD3+MR1tet+CD27+/lowCD161+ cells. Stage 1 MAIT 
cells are only found in the thymus, whereas stage 2 MAIT cells have also been 
observed at low levels in the periphery of young children102. The transition from stage 
2 to stage 3 involves upregulation of PLZF and IL-18R, and the acquisition of 
functional potential to functional maturation occurs extra-thymically. Stage 3 MAIT 
cells are infrequent in the thymus but predominate in cord and peripheral blood. 
However, there are close parallels in the development of mouse MAIT cells and those 
of a human MAIT cells. In the thymus, however, CD4+, and DP MAIT cells are 
represented in more substantial proportions of CD8+ MAIT cells102. A better 
understanding of what regulates the number and function of MAIT cells will require a 
clearer picture of the development and homeostasis of MAIT cells. 
 
2.2.3 Antigen Presentation to MAIT Cells 
For many years after the discovery of MAIT cells, the type of antigens they detect in 
association with MR1 was unknown, which was a major obstacle to understanding the 
biology of these cells. In 2010, two studies, Gold et al. and Le Bourhis et al., first 
demonstrated human MAIT cell activation by bacteria-infected cells in an MR1-
dependent manner, and that they respond to a surprisingly broad range of microbial 
organisms, including many bacteria and yeast95,103. In 2012, a ground-breaking paper 
by Kjer-Nielsen et al. demonstrated that MR1 binds to vitamin B metabolites derived 
from vitamin B2 and vitamin B996. These include 6-FP, folic acid, and several 
ribityllumazines and pyrimidine-based intermediates. Vitamin B2 had the capacity to 
activate MAIT cells. These results were verified with genetic studies, where the 
deletion of genes encoding key enzymes in the riboflavin pathway abolishes an 
otherwise productive MAIT cell response to certain bacteria104. Corbett et al. went on 
to define the key antigens that bind MR1 and result in MAIT cell activation as 5-OP-
RU and 5-OE-RU105. Most of the focus since then been on 5-OP-RU, which is loaded 
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into MR1 tetramers to identify MAIT cells. A mounting list of ligands have been found 
that bind to MR1, include some pharmacological agents and their derivatives, and 
this flags the possibility that the MR1–MAIT cell axis may contribute to certain drug-
hypersensitivity reactions106,107,108. Further characterisation of these antigens is needed 
to understand their relation to the well-defined ribityl antigens. The development of 
MR1-antigen tetramers now permits the specific identification of MAIT cells based on 
T-cell receptor specificity. 
 
2.2.4 MAIT Cell Activation and Effector Functions 
 
Mucosal-associated invariant T cells are considered to span both the innate and 
adaptive arms of the immune system. Once activated MAIT cells are triggered to 
promote a rapid immune response mediated by the release of cytotoxic molecules 
and inflammatory cytokines, such as interferon gamma (IFNγ), perforin, granzymes 
and tumour necrosis factors (TNF),109,110. Upon TCR-dependent recognition of 
microbial antigens, MAIT cells have the capacity to rapidly eliminate bacterially 
infected cells through the production/secretion of inflammatory cytokines such as 
IFNγ, TNFα, and IL-17 and cytotoxic effector molecules like perforin and granzyme 
B. The bacterially derived activation of MAIT cells rapidly induced Grz B and Perforin 
production, licensing these cells to kill their associated target cells109. Cytokines 
produced by MAIT cells not only act directly on infected target cells, but also promote 
the activation of other immune cell populations and thus, assists the orchestration of 
the adaptive immune response through approaches such as dendritic cell (DC) 
maturation111,112. MAIT cell mediation of a potent antimicrobial activity likely 
contributes significantly to the protection against diverse bacterial infections in 
humans. Importantly, van Wilgenburg, B. et al. demonstrated that human MAIT cells 
are also able to activate in vitro in a manner that is TCR independent but dependent 
on IL-18, IL-12 and IL-15 and/or interferon α/β113. Consequently, MAIT cells can be 
activated in various non-bacterial inflammatory conditions in which these cytokines 
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are produced. In particular during human viral infections such as dengue, influenza 
virus, HCV, and HIV113. For the same reasons, MAIT cells may participate in non-
infectious pathological conditions, such as autoimmune disorders and cancer. 
Accordingly, in humans, MAIT cells are the most abundant T cell subset able to detect 
and kill bacterially infected cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.5 The Role of MAIT Cells in Infection, Autoimmunity 
and Inflammation 
 
The function and significance of MAIT cells in health and disease has only started to 
be unravelled. It is becoming increasingly clear that mucosal associated invariant T 
cells are modulated not only in microbial infections but also non-microbial diseases. 
Thus far, MAIT cells have been implicated in various types of immune disorders, such 
as Multiple Sclerosis (MS), Type I diabetes (T1D), Systemic Lupus Erythematosus (SLE) 
and Inflammatory Bowel Diseases114-118. Rouxel et al., first described the alterations in 
MAIT cell in patients with type 1 diabetes and the regulatory role of these cells 
through maintaining gut integrity116. Moreover, Magalhaes. et al. depicted the highly 
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activated phenotype and strong IL-17 profile in MAIT cells of obese and/or diabetic 
patients119. Furthermore, the relevance of MAIT cells in the context of therapeutic 
applications were highlighted by Croxford et al., when they reported MAIT cell 
inhibition of autoimmune disease in the context of experimental autoimmune 
encephalomyelitis120. Likewise, several studies have pointed to a potential 
involvement of MAIT cells in tumour immunity121. Although their contribution to each 
of these pathologies are currently still undefined. Nevertheless, it is clear that 
circulating MAIT cells are dramatically reduced in most diseases and hence, 
elucidating the regulatory mechanisms of MAIT cell activation could have clinical 
implications.  
There is presently a great deal of interest in the identification of other MR1-binding 
antigens, particularly mammalian derived antigens that may link MAIT cells to self-
reactivity and tumour immunity. Intrathymic MAIT cell selection is MR1 dependent, 
evident also in germ-free mice, thus the selecting antigen is likely not of microbial 
origin121. Moreover, selected cells, including some human B cells or tumour cell lines, 
express cell-surface MR1 in the apparent absence of microbial antigens122. This 
evidence together with the suggestions that non–riboflavin-based antigens can bind 
to MR1 and activate some MR1-restricted T cells123, implies that the MR1 ligands are 
even more diverse than is currently appreciated. 
 
2.3 The Transcription Factor Helios 
2.3.1 IKAROS Family of Transcription Factors 
The transcription factor Ikaros, encoded by the Ikzf1 gene, was first described in 1992 
by Georgopoulos et al., by virtue of the protein ability to bind and activate the 
enhancer encoding for the T cell differentiation molecule, CD3δ124. Following this 
discovery, four other proteins, Helios, Aiolos, Eos and Pegasus, that shared a high 
degree of homology to Ikaros, were identified. These DNA-binding proteins now 
comprise the Ikaros family of transcription factors and are characterised by the 
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presence of two sets of highly conserved Krüppel-type zinc finger motifs125. One set, 
located at the amino (N)-terminus, mediates binding to specific DNA sequences, 
while the other, found at the carboxy (C)-terminus, enables the protein to dimerise 
with isoforms and splice variants of itself or alternatively with other family members. 
This distinct structure grants the diverse functional capabilities that have been 
observed by the Ikaros family member proteins, for instance their ability to both 
positively and negatively regulate gene expression through the direct interaction with 
DNA, as well as by forming transcriptional complexes with other proteins126. It is 
believed that the family of proteins are able to regulate gene transcription through 
chromatin remodelling, where they interact in a major transcriptional corepressor 
complex called nucleosome remodelling and histone deacetylase (NuRD) complex127. 
Consequently, this results in nucleosome-disruption and histone deacetylase activity 
that condenses chromatin and most commonly serves to repress the transcription of 
downstream genes. However, the mechanisms of action of these transcription factors 
have yet to be fully defined. 
 
Existing knowledge of the Ikaros family indicates that these transcription factors are 
predominantly implicated in lymphocyte differentiation, but also play a crucial role in 
a wide range of processes that maintain a functional immune system, such as 
apoptosis, cell cycle arrest, proliferation, and differentiation128. Deletion of the Ikaros 
activation and dimerisation domains in mice resulted in a lack foetal T cells, B cells, 
and NK cells, and defective γδ T cells and dendritic cells in adult T cells, due in part 
to the inability of hematopoietic stem cells to differentiate into lymphoid progenitors 
in mice null for Ikaros129. Moreover, several heterozygous mutations associated with 
the DNA-binding domain of Ikaros have been shown to cause a common variable 
immunodeficiency-like syndrome with a striking decrease in B cells and NK cells, in 
addition to T cells, γδ T cells, and dendritic cells130. Additionally, Asanuma et al. 2013 
and Georgopoulos 2017 demonstrated the existence of an association between 
several haematological malignancies and the atypical expression of both Ikaros and 
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Helios; Ikaros in B cell acute lymphoblastic leukaemia (ALL), and Helios in adult T cell 
leukaemia and acute myeloid leukaemia (AML)131,132. Thus, emphasising the crucial 
role this family of transcription factors play in the function and regulation of a normal 
immune response. 
 
2.3.2 Expression of Helios in T Cells 
Helios, encoded by the IKZF2 gene, is expressed in several cell types, but is typically 
limited to the T cell lineage. Originally, Helios was identified as a protein that was 
highly expressed in both murine and human T regulatory cells (Tregs), and 
consequently, much of the research had been focused on its role in the peripheral 
immune tolerance133,134. It was initially postulated that the Helios protein 
differentiated natural Tregs, derived in the thymus, from their peripheral 
counterparts. However, since then Helios expression was shown not to be restricted 
to the natural Treg population, as low-level expression is also manifest in effector T 
cells under certain conditions135. These observations compellingly suggest that 
conventional T cells expressing Helios could sustain Helios expression when 
differentiating into induced Tregs in the periphery.  
 
Currently, there is an accumulating amount of evidence to support the view that 
Helios plays a major role in stabilisation of the non-inflammatory phenotype of Tregs 
and thwarts the production of IL-2 in Tregs by epigenetic silencing136. In support of 
this evidence Nakagawa et al. 2016 and Himmel et al. 2013 showed that in selective 
knock-out models of human memory Tregs, the Helios- Tregs produce more 
proinflammatory cytokines than their Helios-expressing equivalents137,138. Conversely, 
Cai et al. 2009 demonstrated that young Helios knock-out mice show no clear 
immunological phenotype, however, a large fraction of these homozygous pups 
perished for unknown reasons before weaning139. Later in 2016, Sebastian et al. 
showed that the suppressive capacity of Tregs in Helios-/- mice is not severely 
affected, and that older Helios-/- mice develop only a mild autoimmune phenotype, 
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characterised by autoantibodies and dysregulated germinal centre reactions140. 
Consequently, the role of Helios in Tregs still remains elusive. Several studies have 
aimed to ascertain the factors that control the expression of Helios, and thus, have 
identified that in addition to the constitutively expressed Helios in Tregs, the 
expression could also be induced upon TCR-mediated stimulation141. Interestingly, 
this has been observed not only in Tregs but also in effector T cells. It is thus evident 
that Helios has a significant role in regulating effector T cell activity during immune 
responses.  Other factors controlling the expression still remain unidentified, but the 
involvement of NFkappaB transcription factor has been suggested142. 
 
So far, there has been no published evidence of a germline Helios variant that results 
in an immunodeficiency phenotype in humans. However, unpublished research 
conducted in our laboratory have described patients from a single family that display 
a heterozygous Helios loss-of-function mutation with an immunological deficiency-
like phenotype, which echoes that of the Helios knock-out mice phenotype; 
lymphadenopathy with dysregulated germinal centres and aberrations in antibody 
production and augmented IL-2 production from both effector and regulatory T cells. 
These results highlight the importance of Helios’ protein binding domains in 
mediating its functions in both effector and regulatory T cells.  
 
2.3.3 Helios and MAIT Cells 
Mucosal associated-invariant T cells are another population of T cells that express 
relatively high levels of Helios, however, very little is known about its function in these 
cells. Research conducted by Simo Miettinen in our laboratory, demonstrates that the 
expression of Helios in MAIT cells is in fact upregulated upon microbial stimulation, 
indicating that Helios is implicated in the regulation of MAIT cell activation and 
proliferation143. No difference in the levels of Helios expression between CD8, DN 
and CD4 peripheral MAIT cell subsets can be observed, therefore despite the 
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possibility that these subsets of peripheral MAIT cells could have discrete functional 
roles, Helios expression is common to all of them144.    
 
In 2017, Gibbs et al. published a study on MAIT cells from the female genital tract 
and their findings showed that some women had elevated Helios transcription factor 
in MAIT cells in the endometrial region, but not in the cervical region or blood. These 
same cells were stimulated with E. coli and observed for activation markers. These 
Helios++ cells exhibited an increase in IL-17 secretion that was more pronounced than 
in similarly stimulated blood cells145. However, whether Helios affects IL-17 elevation 
remains unclear in the study, for technical reasons. Normally, IL-17 is associated with 
fungal infection immune responses. Moreover, the Helios haploinsufficiency patients 
that were studied in our laboratory showed a reduced number of MAIT cells in their 
circulation, which was not occurring as a result of an increased accumulation to the 
gut mucosal sites. This highlights the importance of the Helios within the MAIT cell 
population. Thus, the role of Helios in MAIT cells is currently unclear but warrants 
further research in this field.  
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3  HYPOTHESES 
We hypothesise that the transcription factor Helios, plays a functional role in 
regulating the activation of mucosal associated invariant T cells, and that the lack of 
this protein would cause a phenotypic change in the levels of effector molecules 
expressed by MAIT cells. 
 
4 AIMS and OBJECTIVES  
The aim of this master’s thesis is to characterise the functional role of Helios in 
peripheral mucosal associated invariant T cells by using siRNA to silence Helios 
expression, and flow cytometry to analyse any potential alterations in MAIT activation 
markers. The objectives of this project are as follows: 
 
1. To validate the upregulation of Helios upon CD3/CD28 stimulation in MAIT 
cells. 
 
2. To determine the time point where expression of Helios is at its highest-
level following stimulation, and thus, the optimal time point at which to 
analyse the potential changes in protein expression of MAIT cells with 
reduced Helios expression. 
 
3. To attenuate the expression of Helios in MAIT cells by at least 50% using 
targeted siRNA. 
 
4. To evaluate differences in the expression of MAIT cells activation markers 
that occur as a result of the knockdown in Helios. 
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5 MATERIALS and METHODS 
 
5.1 Sample Collection and Cell Isolation   
Venous blood samples were drawn into 10 mL Heparin Vacutainers (Beckton 
Dickinson (BD), San Jose, CA) from healthy adult volunteers and rotated from end to 
end several times. Alternatively, buffy coats were obtained from the Finnish Red Cross 
Blood Service (Helsinki, Finland). Donor 1: Male, 57. Donor 2: Male, 60. Donor 3: 
Male, 36. 
 
5.1.1 PBMC Isolation 
Peripheral blood mononuclear cells (PBMCs), the fraction containing the lymphocyte 
population, were isolated using a Ficoll-Plaque (GE Lifesciences, Uppsala, Sweden) 
gradient. Several 50mL falcon tubes containing 15 mL of Ficoll were left to warm to 
room temperature (RT). Meanwhile, the blood collected in each Vacutainer was 
transferred to a clean 50mL falcon and diluted in a 1:3 ratio with room temperature 
(RT) sterile phosphate-buffered saline (PBS). The 30mL of the diluted blood was then 
very carefully overlaid onto each 15mL Ficoll, creating a distinct separation between 
the two layers. The buffy coat, however, was diluted in the bag at a 1:6 ratio with 
sterile PBS at RT, before being transferred in 30mL portions to clean 50mL falcon 
tubes, and then overlaid onto the Ficoll. The falcon tubes were gently placed into a 
swinging bucket rotator centrifuge, and centrifuged for 30 minutes with the break off 
and accelerator set to the minimum, at 1500 rpm, RT. Once centrifuged, the 
interphase fraction could be vigilantly removed, using a pastor pipette, into a fresh 
50mL falcon tube and washed twice in ice cold PBS for 10 minutes at 1200 rpm, +4oC. 
Following the final wash, the cell pellet was resuspended in an appropriate volume 
of sterile PBS for automated cell counting (TC20, Bio-Rad). 
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5.1.2 Enrichment of CD3+ or Vα7.2+ Cells 
Unfractioned PBMCs or enriched CD3+ cells were used to optimise the conditions 
for transfection. Lonza has optimised the transfection settings used for unstimulated 
T cells, and thus, when transfecting PBMCs on these settings, it caused cell death of 
the other mononuclear cell populations, and clumping was evident in the culture. 
Therefore, in future optimisation experiments, the PBMCs were first enriched for 
CD3+ cells prior to transfection. For the experiments that evaluated the knockdown 
of Helios in MAIT cells, we enriched the PBMCs from the buffy coats obtained from 
the Finnish Red Cross Blood Service, for the TCR Vα7.2 to increase the sample 
throughput. Purification of CD3+ T cells or Vα7.2+ T cells from freshly isolated PBMCs 
was performed using the Pan T Cell or Anti-PE Microbead isolation kit (Miltenyi 
Biotec) respectively, with LS Columns in a MidiMACS Separator (Miltenyi Biotec). For 
Vα7.2 enrichment, up to 107 PBMCs per 0.1 mL of FACS staining buffer (PBS, pH 7.4, 
10% heat-inactivated FBS, and 2 mM EDTA) were incubated for 30 minutes at +4oC 
with a Vα7.2 primary antibody conjugated to PE (Biolegend). The cells were washed 
in 1-2mL of MACS buffer (PBS, pH 7.2, 0.5% heat-inactivated FBS and 2 mM EDTA) 
per 107 cells for 10 minutes, at 400 g, in +4oC. Once the supernatant had been 
aspirated, the PBMCs were then resuspended in 80 μl MACS buffer followed by 20 
μl of the Anti-PE MicroBeads per 107 total cells and incubated for 15 minutes in the 
dark at +4oC. The cells were washed again and finally resuspended in 500 µL of MACS 
buffer for up to 10⁸ cells. When higher cell numbers were used, the volumes were 
scaled up accordingly. For Pan T cell isolation, PBMCs were resuspended in 40 μl, 
per 10⁷ cells, in MACS buffer and 10 μl of Pan T Cell Antibody Cocktail is added, so 
that the total volume per 10⁷ cells is 50 μl and incubated for 5 minutes in the dark at 
+4oC. 30 μl of MACS buffer was then added to the cell-antibody mix, followed by 
20μl of the Pan T Cell MicroBead Cocktail per 107 cells, and incubated for 10 minutes 
in the dark at +4oC. The cells are washed and resuspended in the same manner as 
the Vα7.2 enrichment protocol. Meanwhile, the LS columns (Miltenyi) were prepared 
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by rinsing them with 3 mL of MACS buffer. The cell suspension could then be placed 
into the column while positioned in the MidiMACS Separator (Miltenyi), and the flow-
through for the pan T cell enrichment (containing the CD3+ cells) was collected. 
However, as the Vα7.2 enrichment is positive selection, the flow-through could be 
discarded. In this case, the column was removed from the magnetic separator, and 
5mL of MACS buffer was applied to the column, before immediately flushing the 
magnetically labelled cells into a collection tube. The enriched cells were then 
counted using the automated cell counter (TC20, Bio-Rad), and 100,000 cells were 
aliquoted for FACS staining. 
 
5.2 Nucleofection 
Nucleofection is an electroporation-based transfection method that enables the 
transfer of nucleic acids, such as DNA and RNA, into cells by applying a specific 
voltage and reagents. This technique was chosen to transfect the siRNA, as it has 
been specially developed to obtain an optimal result in traditionally ‘hard-to-
transfect’ cell types, such as primary cells. AllStars Hs Cell Death Control, AllStars 
Negative Control and Helios FlexiTube GeneSolution siRNAs (Qiagen) were 
rehydrated according to the instruction of the manufacturer. For nucleofection, 
freshly isolated CD3+ or Vα7.2+ cells were aliquoted to approx. 2.5x106 cells per 
Eppendorf and washed in PBS following their enrichment (centrifuged for 6 minutes, 
at +4oC and 400g) before being resuspended in 100μl of Nucleofector Solution 
Provided in the P3 Primary Cell Transfection Kit (Amaxa, Cologne, Germany). The 
nucleofector reagents have been adapted specially to stabilise this particular cell-
type during nucleofection and creates the conditions needed for direct transfer of 
genetic material into the nucleus during the electroporation. Subsequently, 2 µg of 
pmaxGFP vector (also provided in the P3 Kit by Amaxa) or the appropriate 
concentration of (positive, negative or pooled Helios FlexiTube GeneSolution) siRNA 
were added. In the case that the transfection efficiency could not be evaluated with 
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the AllStars Hs Cell Death Control, siGLO 6-FAM (Horizon) was used. The cell solution 
was then transferred into an electroporation cuvette and placed in the Amaxa™ 4D-
Nucleofector device. Mock control experiments were performed by processing the 
cells in the same way, but without adding the GFP vector or siRNA to the cells. Two 
programmes, FI-115 (high efficiency), and E0-115 (high functionality) were compared 
by evaluating their transfection efficiency with GFP and cell survival. These programs 
differ in the strength of the electric field and the length of the electrical pulses 
(additional details are the proprietary information of Amaxa Biosystems, Cologne, 
Germany). Immediately after nucleofection, 500μl of pre-warmed IMDM media 
supplemented with 10% heat-inactivated FBS was added to the cuvettes. Using the 
small pastor pipettes provided in the kit were used to transfer the cells to a 24 well 
plate containing 1.5 mL of pre-warmed IMDM media supplemented with 10% FBS so 
that they were seeded at approx. 1.25x106 per mL. 
 
5.3 Cell Culture and Stimulation 
The cells were then placed in an incubator at +37°C, 5% CO2, for 15 hours (overnight). 
The media was replaced with fresh IMDM media supplemented with 10% heat-
inactivated FBS and in addition 1X Penicillin-Streptomycin (Sigma-Aldrich). 
Immediately after, the cells were then stimulated using Dynabeads™ Human T-
Activator CD3/CD28 for T Cell Expansion and Activation (ThermoFisher), that had 
been washed in PBS, pH 7.4 with 0.1% bovine serum albumin (BSA) and 2 mM EDTA, 
at a 1:2 ratio of beads to cells. For cytokine stainings, 1μl of GolgiPlug (BD 
Biosciences) per mL of culture was then added for the last 4 hours of stimulation to 
enhance the detection of the cytokines, after which the cells were collected for 
staining. 
5.4 Flow Cytometry  
Techniques like flow cytometry analysis allow the quantification of several parameters 
from individual cells, and thus, permit the characterisation of cell size, structure, 
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specific phenotype, and function of millions of cells in a multi-dimensional way. 
Moreover, Flow cytometry is a convenient method for analysis on a single-cell level. 
However, a substantial limitation of this technique is the relatively small number of 
parameters that can be assessed simultaneously, and consequently, only a restricted 
number of markers that are of interest can be evaluated of the 3-laser flow cytometer. 
In the case of our experimental setup, flow cytometry allows us to validate the 
knockdown (KD) of Helios at a single-cell level, whilst simultaneously discriminating 
between cell populations and displaying the activated phenotype in Helioslow/- MAIT 
cells.  
 
5.4.1 Panel Design and Set Up  
The antibodies used for this project were direct fluorochrome conjugates: Vα7.2–PE, 
Vα7.2-PE-CF594, IL-17-PE-CY7, TNFα-BV711, and CD161-BV605 from Biolegend, 
Helios-eFluor and Granzyme B-APC from Invitrogen, CD8-FITC from ImmunoTools, 
and CD3–BV786, CD4-APC-CY7, Ki-67-FITC, CD25-PE-CF594, and  IFNγ-AF700 
from BD Bioscience. LIVE/DEAD Fixable Aqua Dead Cell Stain or LIVE/DEAD™ 
Fixable Green Dead Cell Stain were used to identify and exclude dead cells within 
the samples. An MR1 tetramer directly conjugated to APC (kindly donated by the NIH 
Tetramer Core Facility, Emory University Vaccine Center, 954 Gatewood Road, 
Atlanta, GA, 30329) was used to compare the use of surrogate markers in healthy 
donors for identifying MAIT cells. The MR1 tetramer technology was developed 
jointly by Dr. James McCluskey, Dr. Jamie Rossjohn, and Dr. David Fairlie, and the 
material was produced by the NIH Tetramer Core Facility as permitted to be 
distributed by the University of Melbourne.   
 
When using multiple fluorochromes in an experiment, several factors may impact the 
quality of the data. The most crucial is discerning which fluorochrome should be 
matched with which antibody. This is because within the collection of fluorochromes 
that can be used with our specific flow cytometer there is a wide range of intrinsic 
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brightness among them, and some antigens are highly expressed while others are 
expressed at lower levels. Additionally, fluorescent emissions from one fluorochrome 
often have spillover into another detector that is designed to measure the signal from 
a different fluorochrome (Figure 4), and thus interferes with that signal. The higher 
the spill over, the lower the resolution, and therefore, the panel design should reflect 
the context of the co-expression of antigens on the cell type of interest, to minimise 
the potential for spectral overlap. In order to do this, wherever possible, the brightest 
fluorochromes were matched with the dimmest antigens, and co-expressed markers 
were spread across different lasers.  
 
Single stain compensation controls are an essential part of an accurate experimental 
setup for multicolour assays. With the use of proper compensations, complex data 
sets from multicolour assays can be visualised and correctly analysed with a well-
designed panel. Single-stained controls for each fluorochrome were prepared using 
one drop of BD Bioscience CompBeads (BD, San Jose, CA), and the addition of the 
single antibody-fluorochrome conjugate to each tube and incubated for 30 minutes 
in the dark at +4oC. 
 
Photomultiplier tubes (PMTs) are the most commonly used detectors for flow 
cytometry. They reside in each channel of the instrument and convert energy of a 
photon into an electronic signal, which can then be amplified by turning up the 
voltage going through the PMT. In setting up the PMT voltages for a new panel, 
several factors were considered. Firstly, minimising the electronic noise in the data to 
ensure that it does not interfere with the measurements of dim or negative events. 
To do this, the minimum PMT voltages settings were determined by calculating 
approximately 2.5X the robust standard deviation of the electronic noise with the cell 
type of interest. Secondly, in order to ensure that the brightest population of the 
stained cells remain within the linear range of the detectors a sample of fully stained 
cells should be run so the brightness of each fluorochrome can be assessed. And 
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lastly, a reasonable resolution of the dim populations at the selected voltages should 
be confirmed in the fully stained cells. Once the PMTs had been determined, the 
single-stained BD CompBeads were checked to confirm that each bead is brightest 
in its primary detector and was then recorded. Finally, the application settings were 
saved to ensure these settings would remain when running the samples at future time 
points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.2 Surface Stainings 
For staining of surface antigens, the T cells were harvested, and the CD3/CD28 
Dynabeads were removed with a magnet prior to the staining and washed in 1mL of 
FACS staining buffer. The antibodies targeted to surface antigens were prepared in 
a master mix in a 50μl volume of Brilliant Stain Buffer (BD Bioscience) per sample 
(Tables 1-5). Live/Dead Fixable Dead Cell Stain was then added to the master mix 
just prior to adding to the cells. The cell pellets were then resuspended in 50μl of the 
antibody master mix per sample and incubated for 30 minutes at +4oC, and in the 
case of no further intracellular staining, the cells were washed once more before 
resuspending in 250μl of FACS staining buffer. When applicable, the cells were 
Figure 4. Spectral Overlap of the Violet Laser. Emission spectra of BV421 and its tandems, 
BV510, BV605, BV650, BV711, BV750, and BV785, excited by the 405nm laser. 
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incubated with MR-1 tetramer (1:2500) in +37oC for 45 minutes and washed before 
continuing to other surface markers. 
5.4.3 Intracellular Stainings 
For staining of transcription factors, Ki67 and cytokines, the cells were fixed and then 
permeabilised after surface staining with FoxP3 Transcription Factor Staining Buffer 
Set (eBioscience). Before fixation, the cells are washed in 1mL of FACS staining buffer 
to remove any of the excess surface antibodies. Meanwhile, 1-part Permeabilisation 
Concentrate was diluted with 3-parts diluent. The cell pellets were then resuspended 
in 500μl of the fixation solution per sample and incubated in +4oC for 45 minutes. To 
permeabilise the cells, they were washed twice in 1X permeabilisation buffer. In the 
meantime, the intracellular antibody master mix was prepared in a 50μl volume of 1X 
permeabilisation buffer per sample (Table 1 and 5). The cell pellets were then 
resuspended in 50μl of the antibody master mix per sample and incubated 30 minutes 
at +4oC. Finally, the cells were washed in 1mL of 1X permeabilisation buffer before, 
resuspending in 250μl of FACS staining buffer, ready for running. 
 
5.4.4 Table of Flow Panels 
Several panels were set up for the different experiments conducted for this project. 
The following tables represent the panels for each series of experiments depicted in 
the results section. In the final experiments where the buffy coats were used to enrich 
for MAIT cells, three separate panels were applied to analyse several components of 
the experiment. First, cells that had just been enriched for Vα7.2 were stained with 
the panel in Table 3 to ensure that the enrichment was successful. Second, a 
separate panel, to check the transfection efficiency, was utilised for GFP transfected 
MAIT cells (Table 4). This was due to the fact that the signal from GFP was no longer 
detectable with the fixation and permeabilisation and thus, could not be incorporated 
into the final panel (Table 5), which was used to assess the knockdown of Helios and 
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the phenotype of the Helioslow/- MAIT cells. The optimal concentrations for antibodies 
were titrated with live PBMCs. 
 
 
Table 1. Helios Upregulation Post Stimulation Panel  
Fluorochrome Target Antigen Dilution 
FITC DCM 1:200 
PE-CF594 Vα7.2 1:20 
BV421 Helios (Intracellular) 1:20 
BV605 CD161 1:20 
BV786 CD3 1:50 
 
Table 2. MR1 Panel  
Fluorochrome Target Antigen Dilution 
FITC DCM 1:200 
PE-CF594 Vα7.2 1:20 
APC MR1 Tetramer 1:2500 
BV605 CD161 1:20 
BV786 CD3 1:50 
 
Table 3. Vα7.2 Enrichment Panel 
Fluorochrome Target Antigen Dilution 
FITC CD8 1:50 
PE Vα7.2 1:20 
APC-CY7 CD4 1:100 
BV510 DCM 1:200 
BV605 CD161 1:20 
BV786 CD3 1:50 
 
Table 4. GFP Panel 
 
Table 5. MAIT Phenotype Panel 
Fluorochrome Target Antigen Dilution 
FITC GFP N/A 
PE Vα7.2 1:20 
BV510 DCM 1:200 
BV605 CD161 1:20 
BV786 CD3 1:50 
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Fluorochrome Surface 
Target Antigen 
Intracellular 
Target Antigen 
Dilution 
FITC   KI-67 1:25 
PE Vα7.2   1:20 
PE-CF594 CD25   1:50 
PE-CY7   IL-17A 1:20 
APC   GRZ B 1:50 
AF700   IFNΓ 1:50 
APC-CY7 CD4   1:100 
e-Fluor   HELIOS 1:20 
BV510 DCM   1:200 
BV605 CD161   1:20 
BV711   TNFα 1:50 
BV786 CD3   1:50 
 
 
5.4.5 Fluorescence Minus One Control (FMO) 
The fluorescence minus one control or FMO was performed as a control in the panel 
that was used to evaluate the knockdown efficiency of Helios in MAIT cells and any 
change in their activated phenotype. This control ensures that gates were placed 
correctly, in the context of data spread due to the multiple fluorochromes. PBMC 
isolation and Vα7.2 enrichment was performed from a buffy coat as described above. 
4x106 enriched Vα7.2 T cells per transfection were transferred to a cuvette and mock-
transfected in the same FI-115 setting, in which the samples were transfected with 
siRNA or GFP vectors.  500μl of supplemented IMDM media was added, as before, 
and the cells were seeded at approx. 1.5x106 per mL in a 24-well plate and incubated 
overnight, before the media was replaced and the cells were stimulated in the same 
manner and timeframe as the experimental samples. However, these cells were 
aliquoted to 11 Eppendorf tubes approx. 1x106 cells per tube and stained with a 
cocktail of antibodies minus one per sample, as represented in the table below 
(Table 6). This allows for the assessment of problems that can potentially arise from 
an unforeseen spillover or unexpected interaction between dyes. The PE FMO could 
not be performed due to the prestaining of Vα7.2 PE that was used to enrich for MAIT 
cells 
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Table 6. – FMO  
Fluorochrome FITC PE-
CF594 
PE-
CY7 
APC AF700 APC-
CY7 
BV421 BV510 BV605 BV711 BV786 
FITC  -   +  +  +  +  +  +  +  +  +  + 
PE  +  +  +  +  +  +  +  +  +  +  + 
PE-CF594  +  -   +  +  +  +  +  +  +  +  + 
PE-CY7  +  +  -   +  +  +  +  +  +  +  + 
APC  +  +  +  -   +  +  +  +  +  +  + 
AF700  +  +  +  +  -   +  +  +  +  +  + 
APC-CY7  +  +  +  +  +  -   +  +  +  +  + 
BV421  +  +  +  +  +  +  -   +  +  +  + 
BV510  +  +  +  +  +  +  +  -   +  +  + 
BV605  +  +  +  +  +  +  +  +  -   +  + 
BV711  +  +  +  +  +  +  +  +  +  -   + 
 
5.4.6 Analysis  
The samples were run using LSR Fortessa (BD Biosciences) and analysed with FlowJo 
(BD Biosciences, LLC). GraphPad Prism software (GraphPad Software, San Diego, 
USA) was used for statistical analysis. The gating strategy to identify MAIT cells is 
represented in the figure below (Figure 5). 
 
 
 
 
 
 
Figure 5. Gating Strategy for the Identification of Mucosal-associated Invariant T Cells in 
Flow Cytometry. SSC: Side scatter, FSC: Forward scatter, DCM: Dead cell marker. 
SSC 
x 
Time 
FSC-A 
x 
FSC-H 
FSC 
x 
SSC 
DCM 
x 
CD3 
CD161 
x 
Vα7.2 
 35 
5.5 Experimental Pipeline 
After optimisation, an experimental pipeline was developed for evaluating 
differences in the protein expression of MAIT cells following the knockdown of Helios 
expression (Figure 6). Utilising the methods previously described, in the series 
depicted below, the ultimate aim in this project was to evaluate any differences in the 
protein expression of MAIT cell activation markers that are a result of the knockdown 
in Helios, could be achieved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6 Ethical Considerations 
Sample collections for the samples from healthy donors follow the Declaration of 
Helsinki, and the relevant EU legislation. The protocols have been reviewed and 
approved by local ethical committees (Ethical Licence: HUS/747/2019). 
 
 
 
 
Figure 6. Experimental pipeline used to evaluate the changes in activation marker 
expression levels of MAIT cells, which occur as result of the knockdown in Helios. 
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6 RESULTS  
 
6.1 Vα7.2 and CD161 as Surrogate Markers for MR1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An MR1 tetramer loaded with 5-(2-oxopropylideneamine)-6-D-ribitylaminouracil (5-
OP-RU), but not 6-formylpterin (6-FP), specifically binds MAIT cells. To identify MAIT 
cells in the peripheral blood of healthy individuals, we performed flow cytometric 
analysis of PBMCs stained with MR1 tetramer loaded with 5-OP-RU, and as a negative 
control, MR1-6-FP tetramer (Figure 7). A clear MAIT cell population is visible in this 
healthy donor (10.3% of total T cells), as specified by the MR1-5-OP-RU loaded 
tetramer staining. 
 
Prior to the discovery and production of the MR1 loaded tetramers, the unique cell 
surface phenotype of MAIT cells, consisting of high expression levels of the C-type 
lectin CD161, the IL-18Rα chain, as well as the ectopeptidase CD26, were often used 
to identify these cells in combination with a monoclonal antibody (mAb) directed 
against the Vα7.2 TCR segment. One recent study examined how well these markers 
define the MAIT cells population in healthy individuals, of specific interest to them, 
was whether all MAIT cells express these markers and whether all T cells identified by 
Figure 7. Identification of MAIT cells from a healthy donor using a MR1 loaded tetramer 
Human MR1 tetramer pre-loaded with 5-OP-RU (left) compared to human MR1 tetramer pre-
loaded with 6-FP (negative control; right), APC labelled, and stained on human PBMCs. A 
population of MAIT cells is clearly visible following staining with MR1-5-OP-RU tetramer (black 
gate). MAIT were identified by first gating for Flow/Singlets/Lymphocytes/Live/CD3+ cells before 
plotting CD3 vs MR1 tetramer. 
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these markers are MAIT cells97. Their findings suggested that identification of MAIT 
cells using Vα7.2 and CD161, IL-18Rα or CD26 mAbs are largely consistent with 
results derived from MR1 tetramer stainings in healthy donors. To confirm these 
findings in our hands, we investigated how accurately CD161 and Vα7.2 markers 
identify MR1-5-OP-RU tetramer+ MAIT cells in three healthy individuals (Figure 8). 
Figure 8. Comparison of MR1-5-OP-RU tetramer and Vα7.2+, CD161hi surrogate 
phenotyping. (A) Black dots represent MR1 tetramer– cells, blue dots represent MR1 tetramer+ 
cells, and the gate represents the Vα7.2+, CD161hi cells from three healthy donors. MAIT cells 
identified with Vα7.2 CD161 were, on average 94.1% positive for MR1. (B) Black dots represent 
Vα7.2-, CD161-/low cells, blue dots represent Vα7.2+, CD161hi cells, and the gate represent MR1 
tetramer+ cells from 3 healthy donors. MAIT cells identified defined by MR1+ were, on average 93.2% 
positive for Vα7.2, CD161. The prior gating was performed as follows: Flow/Singlets/Lymphocytes/ 
Live/CD3+ cells before plotting CD3 vs MR1 tetramer or Vα7.2 vs CD161. 
   
A B 
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First, we determined the proportion of MR1-5-OP-RU tetramer+ cells that are 
represented in the MAIT cell subsets, as defined by CD161hi Vα7.2+ (Figure 8A). In 
all three donors, a high proportion MR1-5-OP-RU tetramer+ was observed in the 
Vα7.2+, CD161hi population, 86.8%, 97.2%, and 98.3%, respectively. Hence, it is clear 
that these markers highly enrich for MAIT cells. Yet, in line with the prior research, 
there exists a small proportion within this population that fail to label with the MR1-
5-OP-RU tetramer. Furthermore, there also exists MAIT cells, classified by the 
recognition of MR1, that are not identified by the markers Vα7.2 and CD161 in healthy 
individuals (Figure 8B). Normal inter-donor variability can be observed in both the 
percentage of MAIT cells from each donor, and the proportion in which MR1-5-OP-
RU tetramer+ cells are co-labelled with Vα7.2 and CD161. However, for the objectives 
of this project, and to simplify the experimental pipeline, we reasoned that the 
identification of MAIT cells using CD3+, Vα7.2+, and CD161hi would be sufficient.  
 
6.2 Upregulation of Helios in MAIT cells upon CD3/CD28 
stimulation  
 
Prior research on the transcription factor Helios in T cells has predominantly been 
focused on regulatory T cells. Here, we evaluate the expression profile of Helios in 
MAIT cells, in order to validate the timepoint in which the upregulation peaks 
following CD3/CD28 stimulation. PBMCs from 3 healthy donors were freshly isolated 
and stimulated with CD3/CD28 before evaluating the expression level of Helios in T 
cells, specifically MAIT cells, in intervals over a period of 48 hours. In mucosal 
associated invariant T cells, identified on the basis of Vα7.2+ and CD161hi, a clear shift 
in Helios expression was observed following stimulation (Figure 9C). A significantly 
higher expression can be observed when compared to non-MAIT cells (Vα7.2+CD161-
). The third individual showed slightly different kinetics for Helios expression 
compared to the other two donors, as the Helios expression profile peaked at 36hs 
rather than 24hs (Figure 9B). A one-way ANOVA was performed on the median 
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fluorescence intensity (MFI) of Helios expression. No statistical significance could be 
observed, however, the 24hs time point showed the closest to significance results 
(Figure 9A). Taking into account that our sample group was small and that we have 
previously observed the same trend in Helios upregulation peaking at 24hs, we 
reasoned that 24hs following stimulation would be the optimal time to analyse the 
effect that reduced Helios expression may have on the phenotype of MAIT cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Upregulation of Helios following CD3/CD28 stimulation of MAIT cells in 
healthy donors. (A) Histogram representing Helios expression at baseline and 24 hs, 36 hs, and 
48 hs after stimulation in independent biological triplicates. A two-way ANOVA analysis was 
performed. No statistical significance could be observed (B) Kinetics of Helios expression from 
each healthy donor (C) Comparison of the level of Helios expression between MAIT cells and non 
MAIT cells (Vα7.2+, CD161-) from each donor at all time points. 1-4. MAIT cells Helios expression 
at baseline, 24hs, 36hs, and 48hs following stimulation, respectively. 5-8. Non-MAIT cells Helios 
expression at baseline, 24hs, 36hs, and 48hs following stimulation, respectively. MAIT cells were 
identified by first gating for Flow/Singlets/Lymphocytes/ Live/CD3+/Vα7.2+CD161hi. 
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The results from this experiment also provided information regarding the expression 
level of the TCR complex following CD3/CD28 stimulation. It became clear that 
following this type of stimulation, T cells downregulate their TCR complex 
considerably. The expression of both CD3 and Vα7.2 was dramatically reduced when 
compared to unstimulated T cells (Appendix). Consequently, the identification of T 
cells and MAIT cells turn out to be more challenging with this type of stimulation. We 
attempted to circumvent this issue in the future experiment, where the accurate 
identification of these populations was required, by enriching for either CD3 or Vα7.2 
prior to CD3/CD28 stimulation. 
 
6.3 Optimisation of Transfection Conditions  
 
6.3.1 Transfection efficiency 
To optimise the transfection efficiency of genetic material in unstimulated T cells, 
nucleofection, using two recommended settings from Lonza specifically developed 
for the transfection of unstimulated primary T cells, was utilised. One setting, FI-115 
has been optimised for the high efficiency of delivery, while the other, EO-115, was 
developed for high functionality. Lonza also provides the media for the transfection 
that has also been optimised for the transfection of T cells. Thus, we evaluated the 
viability of T cells following the exposure to the transfection media and following 
mock transfection on either setting, comparing them to untreated T cells from the 
same donor (Figure 10A). Little difference could be observed in the viability of T 
cells exposed to the transfection media and the untreated T cells. However, as 
expected, the EO-115 and FI-115 mock transfected T cells showed a decrease in 
viability, due to the toxicity of the transfection itself, with the FI-115 transfection 
exhibiting the largest decrease; all measurements were taken at 24hs. To evaluate 
the potential disparity in transfection efficiency between the FI-115 and EO-115 
settings, T cells were transfected with a GFP vector and cultured overnight before 
analysing the expression levels with flow cytometry (Figure 10B). The difference in 
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GFP expression that could be observed between the two settings was sizable. 
Therefore, despite the reduced viability of the T cells transfected with FI-115, the 
considerably higher transfection efficiency observed with this setting directed us to 
investigate whether a similar transfection efficiency could be observed in multiple 
donors, thus we repeated the GFP transfection in three donors with the FI-115 setting. 
(Figure 10C). Considerable variation between donors could be observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next, we attempted to assess the functionality of the siRNA in primary T cells by 
utilising a positive control siRNA, which targets ubiquitously expressed human genes 
essential for cell survival. Knockdown of these genes should induce a high degree of 
cell death, whereas the negative control non-targeting siRNA is used to determine 
Figure 10. Optimisation of the transfection efficiency in unstimulated primary T cells. 
(A) Comparison of the viability between untreated T cells at 24hs and FI-115 or E0-115 mock 
transfected or following the exposure to the transfection (TF) media, in a single donor. (B) GFP 
expression in T cells, 24hs following transfection with pmaxGFP vector when transfected with 
either FI-115 (53.9%) or EO-115 (12.7%) setting, from a single donor. (C) GFP expression in 
MAIT cells from biological triplicates. The mock control from each donor (blue) was used to set 
the gates. T cells and MAIT cells were identified by first gating for Flow/Singlets/Lymphocyte/ 
Live/CD3+/ and Vα7.2+CD161hi, respectively. 
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the non-specific effects of siRNA delivery and provide the baseline to compare with 
siRNA-treated samples. Hence, when the viability of T cells transfected with the 
positive control siRNA is compared to T cells transfected with the negative control 
siRNA, the difference should represent the setting in which the functionality is the 
highest. Biological triplicates comparing the functionality of siRNA, when transfected 
with the different settings for unstimulated primary T cells, were performed and 
evaluated for viability 48hs post transfection. No significant difference between the 
positive control and negative control could be observed with either transfection 
setting (Figure 11A). The viability was also assessed at later time points, but still, no 
difference in viability between positive and negative control could be observed. 
Subsequently, it was evaluated whether the concentration of siRNA contributed to 
the lack of difference observed in the viability of the control siRNAs. A titration series 
of the positive control siRNA were evaluated for viability over a 48h period (Figure 
11B). Here, no difference could be observed at either 24hs or 48hs between the 
different concentrations of positive siRNA and the negative control. However, it was 
clear that the prolonged time had a significant effect on the viability of the T cells 
transfected with siRNA, compared to the mock control.  
 
 
 
 
 
 
 
 
 
 
Figure 11. Optimisation of siRNA functionality. (A) The different settings for transfection 
of unstimulated T cells, FI-115 and EO-115, were evaluated for the functionality of the positive 
control siRNA (50pmol) based on the viability of T cells in biological triplicates (B) A series of 
concentrations of positive control siRNA were evaluated for viability at two different time points, 
24- and 48- hours following transfection (FI-115). One-way ANOVA analysis. Control 1: 
Untreated T cells, Control 2: Transfection media treated T cells. ** = significance. 
A B 
Vi
ab
ili
ty
 
Vi
ab
ili
ty
 
TF Conditions Time 
 ** 
 ** 
 43 
Due to the difficulty with the functionality of the positive control siRNA in primary T 
cells, siGLO, a fluorescently tagged siRNA, was used to investigate if the siRNA was 
able to enter T cells following the transfection, in the same manner as the GFP vector. 
Thus, it would act as a visual indication of siRNA delivery (Figure 12). Here, a slight 
shift in the FITC signal is visible following the transfection of siGLO in T cells. The 
siGLO signal was measured at 15, 48 and 72hs post transfection, and compared to 
the mock transfected control. The highest signal was present at 15hs, and over time 
the signal slightly decreased. At 15hs, a single sample was stimulated with CD3/CD28 
to evaluate if the siRNA signal degenerates at an increased rate with stimulation, 
however, this did not seem to be the case (Appendix). Thus, we concluded that the 
siRNA was able to enter the T cells under the transfection conditions, and hence, the 
issues with the functionality of the positive control siRNA occurred for other reasons 
than entry, perhaps degradation of the siRNA, or incompatibility with primary T cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 12. Transfection of T cells with siGLO. 100pmol of siGLO labelled with 6-FAM was 
transfected (FI-115) to unstimulated primary T cells of a single donor, and evaluated for signal 
at 15hs, 45hs and 72hs using flow cytometry. T cells were identified by first gating for 
Flow/Singlets/Lymphocytes/Live/CD3+.  
 
Mock Transfected - 15hs Transfected w/ SiGLO - 15hs 
Transfected w/ SiGLO - 48hs Transfected w/ SiGLO - 72hs 
 44 
6.3.2 SiRNA Helios Knockdown 
 
Despite the siRNA, that was used to serve as a positive control, not functioning as 
expected, we reasoned that the observation of sufficient levels of siRNA delivery from 
the siGLO transfected T cells warranted testing the functionality of the pooled Helios 
targeted siRNAs, using the FI-115 setting. Two concentrations (100pmol and 
200pmol) of Helios targeted siRNA, were evaluated for their knockdown efficacy in 
MAIT cells, following 24hs of CD3/CD28 stimulation. The negative control siRNA was 
used as a baseline of Helios expression (Figure 13). A clear reduction in the Helios 
expression can be observed in both concentrations of Helios-targeted siRNA when 
compared to the negative control. The MFI of Helios in MAIT cells was evaluated to 
establish the percentage decrease in expression levels compared to baseline. The 
highest concentration of siRNA produced the largest knockdown effect at the protein 
level in this donor (63.9%), in contrast to the 100pmol concentration, which reduced 
Helios expression by 58.6%. Both concentrations of siRNA achieved the target of 
>50% that we aimed to reach. However, the higher concentration was selected for 
further experiments, partly due to the fact the transfection conditions could not be 
fully optimised and hence were perhaps suboptimal in multiple donors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Optimisation of the siRNA concentration targeting Helios. Flow cytometric analysis 
representing the expression of Helios in MAIT cells transfected with 200pmol of negative control siRNA 
(baseline) or two concentrations (100 or 200pmol) of pooled Helios targeted siRNA following 24h 
CD3/CD28 stimulation in a single donor. MAIT cells were identified by first gating for 
Flow/Singlets/Lymphocytes /Live/CD3+/ Vα7.2+ CD161hi. 
 
Negative Control 
siRNA A (200pmol) 
siRNA B (100pmol) 
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6.4 Evaluation of MAIT Cells Phenotype Following 
Knockdown of Helios. 
 
Three buffy coats were obtained from the Finnish Blood service. The blood was 
donated one day (a maximum of 24hs) prior to the collection and processing of the 
buffy coat. Following the PBMC isolation and Vα7.2 enrichment, 200,000 cells from 
each donor were stained (Table 3) to evaluate the enrichment efficiency (Figure 
14A). Both Donor 1 and 2 showed an extremely high Vα7.2+ enrichment efficiency 
(>95% of live CD3+), Donor 3 however had a slightly lower efficiency. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Efficiency of Vα7.2 enrichment and MAIT cell phenotype from the Buffy Coats 
of three donors. (A) Flow cytometric analysis of PBMCs enriched for Vα7.2. 98.2%, 96.4% and 
88.2% of resulting T cells from each donor expressing Vα7.2, respectively. Gating for T cells was 
performed as follows; Flow/Singlets/Live/CD3+ (B) CD4/CD8 phenotype of each donors MAIT cells. 
Majority of the MAIT cell pool is CD8+, however, clear variation can be observed between donors 
DN and CD4+ MAIT subpopulations. The gating strategy for MAIT cells identification was 
implemented as follows: Flow/Singlets/Lymphocytes/Live/CD3+/Vα7.2+CD161hi. 
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CD8 was unable to be included in the final panel (Table 5). Therefore, the proportion 
of CD4+, CD8+ and DN MAIT cells from each donor were ascertained in this panel, in 
order to offer a more complete picture of the variation present within the MAIT cell 
population between donors (Figure 14B). 
 
 
 
 
 
 
 
 
 
 
As a visual indication of delivery and the efficiency of transfection, GFP expression 
originating from the transfected vector, was evaluated. An internal control of delivery 
was not possible due to the fact the GFP signal dissipated upon fixation and 
permeabilisation. Thus, we included a separate sample as a proxy for the transfection 
efficiency, for which only the GFP vector was transfected (Figure 15). Between 
donors, the GFP expression ranged between 21-26% in MAIT cells. However, it is 
important to consider the size of a GFP vector is much larger than siRNA, and thus it 
is likely that the transfection efficiency of siRNA is much higher in reality. 
 
 
 
 
 
 
 
 
Figure 15. GFP expression of transfected MAIT cells from 3 Buffy Coat donors. Flow 
cytometric analysis of enriched Vα7.2 cells from each buffy coat donor which were transfected with 
GFP vector to provide a visual representation transfection efficiency. The expression level ranged 
between 21-26%. The gating strategy for MAIT cells identification was implemented as follows: 
Flow/Singlets/Lymphocytes/Live/CD3+/Vα7.2+, CD161hi. 
Buffy Coat Donor 1  
MAITs 
 
Buffy Coat Donor 2  
MAITs Buffy Coat Donor 3 MAITs 
Figure16. The knockdown of Helios in MAIT cells from 3 Buffy Coat donors. Flow 
cytometric analysis representing the expression of Helios in MAIT cells transfected with a 
negative control (baseline) or 200pmol of pooled Helios targeted siRNA, following 24h CD3/CD28 
stimulation for each buffy coat donor. Reduction when compared to negative control D1. 55.9%, 
D2. 69.7%, D3. 55.2%. The gating strategy for MAIT cells identification was implemented as 
follows: Flow/Singlets/Lymphocytes/Live/CD3+/Vα7.2+CD161hi. 
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Following the transfection and the stimulation of the enriched Vα7.2+ T cells, the cells 
were stained with the MAIT cell phenotype panel (Table 5). Following the application 
of the gating strategy based on the FMO from each fluorochrome (excluding PE), 
MAIT cells were identified, and the Helios expression was evaluated to confirm the 
knockdown in each donor, compared to the mock and negative control. MFI values 
from all three donors indicated a higher than 50% knockdown, with an average of 
60.3% reduction (Figure 16).  
 
 
 
 
 
 
 
 
 
 
 
 
No significant differences could be detected in the expression levels between the 
Helios knocked down MAIT cells and the controls in any of the markers investigated 
(Figure 17). Ki-67, a marker of proliferation, showed no signal in any of the samples 
(Appendix). Moreover, few circulating MAIT cells are known to express IL-17, as this 
marker is typically expressed at higher levels in tissue resident MAIT cells146. This is in 
line with what we can observe here, with the knockdown in Helios showing no 
difference. Nevertheless, both TNFα and IFNγ, which are typically expressed highly 
in activated circulating MAIT cells, exhibited a much lower signal, from all of the 
donors MAIT cells that had been transfected, than what would be expected.  
 
Figure 17. Evaluation of the activation markers of MAIT cells following the 
knockdown of Helios in MAIT cells from 3 Buffy Coat donors. Flow cytometric analysis 
was performed to evaluate changes in the expression level of the activation markers IL-17, 
TNFα, IFNγ, GrzB, CD25 between Helios knocked down MAIT cells and controls. No significant 
differences could be detected. The gating strategy for MAIT cells identification was 
implemented as follows: Flow/Singlets/ Lymphocytes/Live/CD3+/Vα7.2+CD161hi/CD4-.Gating 
for each marker was devised according to the corresponding FMO. 
Helios siRNA 
Mock 
Negative  
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When we compared the expression level of the activation markers to non-transfected 
cells, however, it became evident that there was a clear difference in the level of 
soluble activation markers between mock transfected and non-transfected MAIT cells 
(Figure 18). This indicates that the functionality of MAIT cells following FI-115 
transfection dramatically reduces the levels of effector molecules, specifically soluble 
cytokines, that are typically upregulated upon stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. The functionality of MAIT Cells transfected with the high efficiency setting, 
FI-115. Flow cytometric analysis of MAIT cells from the third buffy coat donor was performed to 
analyse how the FI-115 transfection of MAIT cells impacted their functionality. Mock transfected 
MAIT cells (right column), which were stimulated with CD3/CD28 for 24hs, are compared to non-
transfected stimulated MAIT cells (centre column) from the same donor. Gating for each marker 
was devised according to the corresponding FMO (left column). The gating strategy for MAIT cells 
identification was implemented as follows: Flow/Singlets/Lymphocytes/Live/CD3+/Vα7.2+CD161hi 
/CD4-. Each marker was gated against SSC, and Ki-67 was excluded as no signal was observed 
from any sample. 
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7 DISCUSSION 
 
The high frequency, potent antimicrobial activity and proinflammatory capacity of 
MAIT cells provide an appealing topic that is of great interest for both basic 
immunology and clinical research. Here, we aimed to increase our understanding of 
peripheral blood MAIT cells in healthy individuals by seeking to comprehend the role 
of Helios in their activation. 
 
The identification of MAIT cells has typically been accomplished with flow cytometry 
by combining Vα7.2 expression with high expression of CD161, however, since the 
development of the MR1-5-OP-RU loaded tetramer, which directly recognises MAIT 
cells by their MR1-restricted TCR specificity, this has become the most common and 
the gold standard of MAIT cell identification. Nevertheless, it has been acknowledged 
that in healthy donors, surrogate phenotyping techniques highly correspond to MAIT 
cells, defined by MR1 positivity97. Here, we evaluate how tightly these surrogate 
markers correlate with MR1 tetramer staining in donors that are considered to be 
healthy, and thus, whether it would be an appropriate method to identify MAIT cells 
for our experimental design. Our data confirmed what has been previously 
established, that MR1+ cells highly correlate with Vα7.2+ CD161hi in healthy donors, 
yet, a small proportion of non-MAIT cells are falsely identified using these surrogate 
markers, and a minor subset of MAIT cells are excluded. Prior research has also shown 
that in situations where MAIT cell frequencies are reduced, such as with age or in 
disease settings, the proportion of non-MAIT cells in surrogate marker-defined 
populations increase147.  
 
Furthermore, it has been clearly demonstrated that the CD8+ and DN Vα7.2, CD161 
subsets more closely represent the MAIT cell population than that of the CD4+ 
counterparts81. In one study, a population of T cells defined as CD161+Vα7.2+CD4+ 
exhibited a differential production of specific cytokines148. This could have resulted 
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from the fact that not all CD4+CD161+Vα7.2+ T cells are MAIT cells, based on MR1 
recognition. However, CD4+ MAIT cells identified on the basis of MR1 recognition 
have also been shown to produce more IL-2 than other MAIT cell populations, and 
thus this population could potentially play a discrete role within the immune system82. 
Consequently, we reasoned that the CD4+Va7.2+CD161hi population should be 
excluded when evaluating the phenotypic functionality of MAIT cells. 
 
The induced expression of Helios upon stimulation of the MAIT cell population 
emulates that of what has been observed in Tregs149. A rapid upregulation 
immediately following stimulation that peaks around 24hs. A similar expression 
pattern can also be observed upon bacterially derived stimulation, indicating that 
Helios plays an important role in the function and activation of MAIT cells143. In 
lymphocytes, Helios is known to act mainly as a transcriptional repressor. However, 
in contrast to Tregs, MAIT cells exhibit cytotoxic and effector functions, and thus, 
Helios has the potential to perform opposing roles within different T cell populations.  
 
Moreover, earlier work performed in our laboratory observed an increase in 
proinflammatory signalling and production of proinflammatory cytokines in Helios 
haploinsufficient patients in a single family, signifying that the lack of Helios 
expression in T cells could cause heightened baseline levels of activation which thus 
leads to immune dysregulation. Additionally, one defining feature of these Helios 
haploinsufficient patients was the striking reduction in the number of MAIT cells in 
the peripheral blood, and the small number of Vα7.2+CD161hi T cells that could be 
detected in patients exhibited lower levels of Helios expression than healthy controls. 
These findings led us to take a greater interest in the observation of proinflammatory 
activation markers of MAIT cells, such as IFNγ, TNFα, and Granzyme B, following the 
knockdown of Helios. 
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Due to the restricted number of markers that we could analyse simultaneously with 
flow cytometry, a clear limitation of our study, we were unable to evaluate all the 
markers that were of interest to us. Thus, we designed the panel to include what were 
believed to be the most relevant markers. Interestingly, however, it has been 
established that Helios represses IL-2 production in T cells136. Thus, the inclusion of 
IL-2 to the panel was of interest, but logistics made it difficult to include. Still, it is a 
marker that should certainly be evaluated in future studies, alongside markers such 
as Perforin, IL-7, IL-22 and IL-18R. 
 
This study endeavoured to optimise a transfection method for the knockdown of 
Helios in MAIT cells. Preferably all the experiments executed to optimise the 
transfection conditions should have been performed in triplicates, however, due to 
the difficulties with the positive control siRNA, complete optimisations became 
challenging, and resources were directed towards solving the issue. The final 
condition utilised for the transfections were sub-optimal. However, a substantial 
knockdown in the expression of Helios at the protein level was achieved with a high 
concentration of Helios targeted siRNA. Nevertheless, lower concentrations of 
siRNAs are advised to avoid the heightened effects of off-targets150. 
 
In accordance with that, further experiments to optimise the transfection conditions 
for our experimental design should have been conducted. Primary T cells are difficult 
cells to transfect, and the impact of electroporation on T cell function, and not only 
viability, should have been considered. Hence, an evaluation of the functionality of 
the T cells following the transfection on the different settings, but prior to the addition 
of siRNA, would have been beneficial.  
 
No significant differences could be detected in any of the markers between MAIT 
cells with reduced Helios levels and their controls. However, due to the high toxicity 
of the transfection conditions, we detected reduced functionality, which could explain 
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why we were unable to detect any differences in the expression levels of those 
markers. The soluble markers were particularly affected by the transfection, whereas 
the surface markers did not appear to be as impacted by the transfection. On the 
other hand, however, despite the considerable effects of the transfection on the 
functionality of the MAIT cells, it is also possible that Helios does not regulate any of 
the markers that we included in the panel, and comparable results may be observed 
with a gentler transfection setting and an equivalent knockdown effect.  
 
One article describing MAIT cells from different age groups found that the 
percentages of IL-17-expressing cells in the circulating MAIT cells of healthy subjects 
were very low (around 1%−3%)146. These results are comparable with the data we 
observed, however, it is unreasonable to make any conclusions regarding the role 
Helios may or may not have on  the expression of IL-17, or any of the other cytokines, 
due to the stunted expression of the soluble effector molecules following 
transfection. The expression levels of the CD25 however, were not so evidently 
impacted by the toxicity of the transfection, which theoretically could signify that 
Helios does not play any role in the upregulation of this marker upon activation in 
MAIT cells. However, further results would need to be ascertained to be able to make 
this conclusion. No Ki-67 expression was detected in any of the samples, however, 
due to the short stimulation and culture time of the experimental pipeline, it is not 
surprising, as proliferation in T cells typically occurs after 48hs in culture. 
 
Therefore, from these results, it is difficult to conclude any clear role for Helios in the 
activation of MAIT cells, predominantly due to the fact that the transfection harshly 
affected the functionality of these cells, and consequently, our data is inconclusive. 
 
All in all, there is still plenty of room for further optimisations of this experimental set 
up as well as further studies which could be performed to supplement these results 
and further validate the role of Helios in MAIT cells activation.  
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8 FUTURE RESEARCH  
In this thesis, the experimental pipeline for the knockdown of the transcription factor 
Helios in primary MAIT cells was established. However, further optimisations are 
required to fully evaluate the effects reduced Helios expression has on the phenotype 
of MAIT cells during activation. 
 
Research that would follow directly on from this project would be to establish the 
effects of a gentler transfection on the functionality of MAIT cells. This would 
subsequently require further optimisation of the concentration of siRNAs required to 
achieve a substantial knockdown effect in Helios. With this in mind, the evaluation of 
any potential off-target effects could be performed by assessing the phenotypic 
outcome following the transfection of each individual siRNA, rather than only the 
pooled siRNAs. 
 
Once accomplished, and the experimental pipeline of this project has been repeated, 
the results of any phenotypic change of MAIT following the knockdown of Helios 
should be validated with a “closer to in vivo” type stimulation, a MAIT: Monocyte co-
culture that can provide the opportunity for bacterially derived stimulation. Moreover, 
the ChIP-seq method could be used to analyse the interaction of Helios with DNA 
and identify its binding sites in MAIT cells.  
 
Furthermore, an evident factor that limits the ability to fully comprehend the effect of 
the knockdown of Helios in MAIT cells is the restricted number of markers we can 
evaluate with flow cytometry. To evade this issue and to further validate our results, 
single-cell RNA sequencing could be utilised to gain a more precise understanding 
of the transcriptome in MAIT cells, with reduced Helios expression. 
 
Despite the immense progress we have seen within the MAIT field in recent years, 
there is much research still to be done to fully understand the role of MAIT cells in 
the immune system.  
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11 APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1. A Comparison of  GFP expression at 24hs and 48hs following the transfection 
of a GFP vector in T cells. GFP expression in T cells of a single donor, 24hs or 48hs following 
transfection with pmaxGFP vector when transfected with either FI-115 or EO-115 setting.  FI-
115 shows a considerably higher expression level at both time points than the EO-115 setting. 
T cells were identified by gating for Flow/Singlets/Lymphocyte/ Live/CD3+. 
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Figure 2. Representation of the Gating Strategy and Backgating utilised to Identify 
MAIT cells. Backgating is an advanced technique in flow cytometry data analysis, which 
illustrates a terminal gate of interest overlaid on previous points in the gating hierarchy 
without regard to that gate being illustrated. In settings where the BV605 – CD161 signal 
is low, and thus the identification of the MAIT cells becomes more difficult, backgating was 
applied to better refine the gating. 
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Figure 4. Efficiency of Vα7.2 Enrichment from Live PBMCs of Three Buffy Coats Donors. 
(A) Flow cytometric analysis of PBMCs enriched for Vα7.2. of the total Live cells from each donor 
expressing Vα7.2, respectively. Gating for T cells was performed as follows; Flow/Singlets/Live. 
   
 PE - Vα7.2 
Buffy Coat Donor 1  
Live+ 
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Figure 3. Transfection of T cells with siGLO and subsequent CD3/CD28 stimulation. 
100pmol of siGLO labelled with 6-FAM was transfected (FI-115) to unstimulated primary T 
cells of a single donor, rested for 15hs and then stimulated for 24hs, before being evaluated for 
signal using flow cytometry. T cells were identified by first gating for Flow/Singlets/ 
Lymphocytes/Live/CD3+.  
Transfected w/ SiGLO -15hs 
and 24hs stimulation 
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Figure 5. Representation of Ki-67 signal from the Buffy Coat Donors. Flow cytometric data 
of CD4- MAIT showing no signal from the proliferation marker KI-67. No change can be observed 
in the MAIT cells with a reduced expression of Helios. The gating strategy for MAIT cells 
identification was implemented as follows: Flow/Singlets/Lymphocytes/Live/CD3+/Vα7.2+CD161hi 
/CD4-. 
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Figure 6. Representation of the Down regulation in CD3 and Va7.2 upon CD3/CD28 
Stimulation. Flow cytometric data showing that the markers, CD3 and Va7.2, in T cells are 
downregulated when stimulated with anti-CD3/CD28. The gating strategy for MAIT cells 
identification was implemented as follows: Flow/Singlets/Lymphocytes/Live/CD3+/Vα7.2+CD161hi. 
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